Kodiak Sciences is a biopharmaceutical company developing treatments for eye diseases affecting the retina. Its main candidate, tarcocimab tedromer (KSI-301), is an antibody designed to block vascular endothelial growth factor and has completed Phase 3 testing for certain retinal vascular conditions while undergoing Phase 3 or Phase 2/3 studies for diabetic retinopathy, wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. The company also has earlier-stage candidates targeting inflammation and growth factors in retinal diseases.

entry readiness 0 · NOT READY · exit proximity 70

Value area 29.21–91.06 · 0% of 120d volume overhead · clean runway